Identifying and assessing putative allosteric sites and modulators for CXCR4 predicted through network modeling and site identification by Ligand Competitive Saturation

dc.contributor.authorİnan, Tuğçe
dc.contributor.authorFlinko, Robin
dc.contributor.authorLewis, George K.
dc.contributor.authorMacKerell, Alexander D., Jr.
dc.contributor.authorKürkçüoğlu, Özge
dc.contributor.authorID0000-0001-8287-6804
dc.contributor.authorID0000-0003-0228-3211
dc.contributor.departmentKimya Mühendisliği
dc.date.accessioned2024-09-26T08:58:35Z
dc.date.available2024-09-26T08:58:35Z
dc.date.issued2024
dc.description.abstractThe chemokine receptor CXCR4 is a critical target for the treatment of several cancer types and HIV-1 infections. While orthosteric and allosteric modulators have been developed targeting its extracellular or transmembrane regions, the intramembrane region of CXCR4 may also include allosteric binding sites suitable for the development of allosteric drugs. To investigate this, we apply the Gaussian Network Model (GNM) to the monomeric and dimeric forms of CXCR4 to identify residues essential for its local and global motions located in the hinge regions of the protein. Residue interaction network (RIN) analysis suggests hub residues that participate in allosteric communication throughout the receptor. Mutual residues from the network models reside in regions with a high capacity to alter receptor dynamics upon ligand binding. We then investigate the druggability of these potential allosteric regions using the site identification by ligand competitive saturation (SILCS) approach, revealing two putative allosteric sites on the monomer and three on the homodimer. Two screening campaigns with Glide and SILCS-Monte Carlo docking using FDA-approved drugs suggest 20 putative hit compounds including antifungal drugs, anticancer agents, HIV protease inhibitors, and antimalarial drugs. In vitro assays considering mAB 12G5 and CXCL12 demonstrate both positive and negative allosteric activities of these compounds, supporting our computational approach. However, in vivo functional assays based on the recruitment of β-arrestin to CXCR4 do not show significant agonism and antagonism at a single compound concentration. The present computational pipeline brings a new perspective to computer-aided drug design by combining conformational dynamics based on network analysis and cosolvent analysis based on the SILCS technology to identify putative allosteric binding sites using CXCR4 as a showcase.
dc.identifier.citationInan, T., Flinko, R., Lewis, G.K., MacKerell, A.D. and Kurkcuoglu, O. (2024). "Identifying and Assessing Putative Allosteric Sites and Modulators for CXCR4 Predicted through Network Modeling and Site Identification by Ligand Competitive Saturation". The Journal of Physical Chemistry B, 128 (21), 5157–5174. https://doi.org/10.1021/acs.jpcb.4c00925
dc.identifier.endpage5174
dc.identifier.issue21
dc.identifier.startpage5157
dc.identifier.urihttps://doi.org/10.1021/acs.jpcb.4c00925
dc.identifier.urihttp://hdl.handle.net/11527/25450
dc.identifier.volume128
dc.language.isoen_US
dc.publisherAmerican Chemical Society
dc.relation.ispartofThe Journal of Physical Chemistry B
dc.rights.licenseCC BY 4.0
dc.sdg.typeGoal 9: Industry, Innovation and Infrastructure
dc.subjectchemokine receptors
dc.subjectcancer
dc.subjectCXCR4
dc.titleIdentifying and assessing putative allosteric sites and modulators for CXCR4 predicted through network modeling and site identification by Ligand Competitive Saturation
dc.typeArticle

Dosyalar

Orijinal seri

Şimdi gösteriliyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
Ad:
4c00925.pdf
Boyut:
10.44 MB
Format:
Adobe Portable Document Format

Lisanslı seri

Şimdi gösteriliyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
Ad:
license.txt
Boyut:
1.58 KB
Format:
Item-specific license agreed upon to submission
Açıklama